



DLA Piper (Canada) LLP
Suite 6000, 1 First Canadian Place
PO Box 367, 100 King St W
Toronto ON M5X 1E2
www.dlapiper.com

August 25, 2022

VIA SEDAR

British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Ontario Securities Commission
New Brunswick Financial and Consumer Services Commission
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Prince Edward Island
Securities NL, Government of Newfoundland and Labrador

**Re: Bright Minds Biosciences Inc.
Prospectus Supplement dated August 25, 2022**

We refer to the prospectus supplement (the “**Supplement**”) of Bright Minds Biosciences Inc. (the “**Company**”) dated August 25, 2022 to the base shelf prospectus of the Company dated June 7, 2021, relating to the sale of units of the Company.

We hereby consent to the references to our name, DLA Piper (Canada) LLP on page (iii), under the heading “Legal Matters” in the Supplement, under the heading “Interest of Experts” in the Supplement, and to the use of our name, DLA Piper (Canada) LLP, and our opinions under the heading “Eligibility for Investment” in the Supplement, which opinions are provided as of the date of the Supplement.

We confirm that we have read the Supplement and that we have no reason to believe that there are any misrepresentations in the information contained in the Supplement that are derived from our opinions in the Supplement or that are within our knowledge as a result of the services we performed in the preparation of the Supplement.

Sincerely,

(signed) “*DLA Piper (Canada) LLP*”